News
-
The European Commission has granted marketing authorization for Nycomed’s single dose Instanyl fentanyl nasal spray for the treatment of breakthrough pain in cancer patients. A multi-dose Instanyl product was approved by the EC in 2009… Read more . . .
-
The FDA has approved Novartis’s Arcapta Neohaler with a 75 mcg once-daily dose of indacaterol for the treatment of COPD. Novartis sells an indacaterol inhaler in Europe as the Onbrez Breezhaler. The company plans to… Read more . . .
-
The FDA has approved Archimedes Pharma’s Lazanda fentanyl nasal spray for the treatment of breakthrough pain in cancer patients 18 years old and older. The product is already marketed in five European countries, where it… Read more . . .
-
Forest Laboratories and Almirall have submitted a new drug application to the FDA for their inhaled aclidinium bromide, a dry powder long-acting inhaled antimuscarinic agent for the treatment of COPD. Forest has licensed the US… Read more . . .
-
NVA237, a glycopyrronium bromide dry powder formulation licensed by Novartis from Sosei and Vectura has met its primary endpoint in the Phase 3 GLOW2 trial. According to Sosei, the study showed that NVA237 had similar… Read more . . .
-
Particle engineering company Prosonix has secured £11.4M from a group of investors led by French venture company Ventech. Other investors involved in this round of financing include Entrepreneurs Fund, Quest for Growth, and Solon Ventures,… Read more . . .
-
Pulmatrix, which recently launched its new iSperse dry powder delivery system, has announced the promotion of Robert Clarke to Chief Scientific Officer (CSO) and VP of Research and Development. In addition, the company has added… Read more . . .
-
Researchers from the University of Goteborg, Sweden, have found that an intranasal cellulose powder significantly reduced allergic rhinitis symptoms in children. The double-blind study involved 53 children with allergies to birch pollen. Nils Åberg, associate… Read more . . .
-
Gerresheimer will spend €12m to add approximately 5,000 sq. meters to the plastics production area at its manufacturing facility in Horsovsky Tyn, Czech Republic. The plant produces medical plastic devices, including insulin pens and inhalers.… Read more . . .
-
The Committee for Medicinal Products for Human Use (CHMP) has recommended against granting a marketing authorization to Pharmaxis’s Bronchitol inhaled dry powder mannitol formulation for the treatment of cystic fibrosis. The CHMP had previously indicated… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.